AstraZeneca: Forxiga approved in China
(CercleFinance.com) - AstraZeneca's Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage renal disease, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease at risk of progression for people with or without type 2 diabetes.
The condition affects 850 million people worldwide. However, diagnosis rates remain low and up to 90% of patients are unaware that they have the disease.
The approval from China's State Administration of Medical Products is based on the positive results of its Phase III trial.
Forxiga (known as Farxiga in the US) is now approved in 100 countries worldwide, including the US, EU and Japan.
AstraZeneca shares closed down about 0.7% in London yesterday.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The condition affects 850 million people worldwide. However, diagnosis rates remain low and up to 90% of patients are unaware that they have the disease.
The approval from China's State Administration of Medical Products is based on the positive results of its Phase III trial.
Forxiga (known as Farxiga in the US) is now approved in 100 countries worldwide, including the US, EU and Japan.
AstraZeneca shares closed down about 0.7% in London yesterday.
Copyright (c) 2022 CercleFinance.com. All rights reserved.